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INTRODUCTION
Esophageal cancer is an important health problem 
worldwide, with an increasing incidence and high mor-
tality. It has a poor prognosis and is often diagnosed 
at a late stage. At the time of diagnosis, 60% of the 
patients are only suitable for palliative therapy(2).
There are two major types of esophageal cancer: 
adenocarcinoma and squamous cell carcinoma. 
Squamous cell cancer arises mainly from the upper 
and middle esophagus. Adenocarcinoma affects the 
distal esophagus of younger patients and it is usually 
detected in an earlier stage(6). The known risk factors 
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ABSTRACT – Context - Esophageal cancer is often diagnosed at an advanced stage and has a poor prognosis. Most patients with 
advanced esophageal cancer have significant dysphagia that contributes to weight loss and malnutrition. Esophageal stenting is a 
widespread palliation approach, but unsuitable for cancers near the upper esophageal sphincter, were stents are poorly tolerated. 
Generally, guidelines do not support endoscopic gastrostomy in this clinical setting, but it may be the best option for nutritional 
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patients with unresecable esophageal cancer histological confirmed, in whom stenting was impossible due to proximal location, and 
chemotherapy or radiotherapy were palliative, using gastrostomy for enteral nutrition. Clinical and nutritional data were evaluated, 
including success of gastrostomy, procedure complications and survival after percutaneous endoscopic gastrostomy, and evolution 
of body mass index, albumin, transferrin and cholesterol. Results - Seventeen males with stage III or IV squamous cell carcinoma 
fulfilled the inclusion criteria. Mean age was 60.9 years. Most of the patients had toxic habits. All underwent palliative chemothe-
rapy or radiotherapy. Gastrostomy was successfully performed in all, but nine required prior dilatation. Most had the gastrostomy 
within 2 months after diagnosis. There was a buried bumper syndrome treated with tube replacement and four minor complications. 
There were no cases of implantation metastases or procedure related mortality. Two patients were lost and 12 died. Mean survival 
of deceased patients was 5.9 months. Three patients are alive 6, 14 and 17 months after the gastrostomy procedure, still increasing 
the mean survival. Mean body mass index and laboratory parameters were roughly stable 1 and 3 months after the gastrostomy 
procedure. Conclusions - In patients with advanced upper esophageal cancer where only palliative treatment is possible, nutritional 
support is easily achieved with percutaneous endoscopic gastrostomy, allowing patients to be at homes, surviving a significant period 
of time. Percutaneous endoscopic gastrostomy feeding should be considered as standard definitive nutritional palliation in patients 
with upper esophageal cancer, unsuitable for esophageal stenting.
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for esophageal cancer are smoking, alcohol consump-
tion, chronic gastroesophageal reflux disease, Barrett’s 
esophagus, exposure to nitrosamines, ingestion of lye, 
Fanconi’s anemia, achalasia, Plummer-Vincent webs, 
and tylosis(3). Progressive dysphagia and rapid weight 
loss are the initial symptoms in most patients.
Primary therapeutic options include surgical 
resection of  the primary tumor, chemotherapy, 
and radiotherapy. Selection is made depending on 
the tumor stage and location, histological type and 
patient’s medical condition. Frequently it is possible 
to combine therapies, chemotherapy plus surgery or 
chemotherapy and radiotherapy plus surgery. For 
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advanced tumors, there are different options of  palliative 
treatment including brachytherapy, chemotherapy and 
endoscopic palliation techniques such as esophageal dila-
tation, intraluminal stents, laser therapy or photodynamic 
therapy(2). 
Most patients with advanced esophageal cancer have 
significant dysphagia that contributes to weight loss and 
malnutrition, with a negative impact on the disease course 
and quality of  life(5, 9). Therefore, restoring or preserving 
swallowing and maintaining nutritional status are primary 
goals of palliation. Esophageal dilatation and stenting are 
a simple and widespread palliation approach. It allows pa-
tients to have an almost normal oral intake. Unfortunately, a 
large number of cancers arise in upper esophagus, and stents 
placed near the upper esophageal sphincter, less than 1-2 
cm, are poorly tolerated by most patients. For these patients 
with proximal cancers, gastrostomy may be the best option 
for nutritional support.
Even when surgery, chemotherapy or radiotherapy are 
intended to be curative, they frequently compromise oral 
intake for a large period. Percutaneous endoscopic gastros-
tomy (PEG) may be used for transitory nutritional support 
during this period. Conversely, PEG may be used to provide 
palliative enteral nutrition in patients with advanced cancer 
and no expectation of resuming oral intake. As a general rule, 
guidelines do not support PEG tube placement in evidence 
of terminal disease, with rapidly progressive tumor, severe 
malnutrition, and life expectancy less than 1-2 months(8, 14). 
Nevertheless, in individual cases PEG may be used as an 
alternative to nasogastric tubes or other nutritional options, 
in order to prevent patients from starving.
The aim of the present study was the retrospective evalua-
tion of the clinical and nutritional evolution of patients with 
upper esophageal cancer using PEG for comfort palliative 
nutrition.
MATERIALS
From the clinical files of our enteral nutrition team, we 
selected adult patients with unresecable esophageal cancer 
in whom stenting was impossible and chemotherapy or 
radiotherapy were palliative, without intending a definitive 
solution of dysphagia. 
Patients were included with:
1. Histological confirmed carcinoma of  the proximal 
esophagus. 
2. Unsuitable curative approach due to cancer extension 
or patient condition. 
3. Proximal cancer location preventing esophageal stent 
placement.
4. Endoscopic gastrostomy as definitive nutritional pal-
liation.
Patients with surgical gastrostomy were excluded.
The collected data of the patients included:
1. Clinical data: age and gender, toxic habits, stage of the 
tumor, success or failure of PEG tube insertion, pro-
cedure complications and survival after gastrostomy.
2. Available nutritional and laboratorial markers, at the 
time of gastrostomy and 1 and 3 months later: body 
mass index (BMI), serum albumin, serum transferrin 
and serum total cholesterol.
RESULTS
Seventeen patients fulfilled the inclusion criteria. They 
were all male. Patient’s age ranged from 39 to 78 years (mean 
age: 60.9 ± 12.8 years). All 17 were diagnosed as having 
squamous cell carcinoma (SCC). Most of  the patients 
had toxic habits (14 smokers and 11 with major alcoholic 
intake). All patients presented at an advanced cancer stage, 
12 (70%) in stage IV, the remaining 5 (30%) in stage III. 
All underwent palliative chemotherapy, radiotherapy or 
booth combined.
PEG Procedure
The enteral feeding team discussed the insertion of  a 
PEG tube with the patients and the caregivers. All of  them 
understood the potential and the limitations of  the proce-
dure. Most of  the 17 patients, J (76%) had the gastrostomy 
within 2 months after the diagnosis (Table 1). The standard 
pull method was used in all patients. In nine cases (53%), 
there was an esophageal stenosis requiring prior dilatation. 
All procedures were performed under conscious sedation, 
administered according to the patients needs. Gastrostomy 
was successfully performed in all of  them and there were 
no cases of  unsuccessful attempts of  PEG tube placement. 
The procedure was performed during a 24-48 hours hospital 
stay and all patients were safely discharged to their homes. 
Follow-up was carried out in an outpatient basis.
TABLE 1. Time from diagnosis to gastrostomy
Time from diagnosis to gastrostomy (month)
<1 5
1-2 8
3-4 4
>4 0
 
Complications
There was one major complication. It was a buried 
bumper syndrome (BBS) in a 61 years old patient with a SCC 
stage IV, treated with PEG tube replacement. Minor com-
plications occur in four patients. Three with local infection 
around the PEG tube, that were treated with dressings and 
oral antibiotics, and in one case there was a leakage and the 
PEG tube had to be replaced for a larger one. There were no 
cases of implantation metastases. There was no procedure 
related mortality.
In one patient there was a mediastinitis after esophageal 
dilatation of a cancer obstruction that was treated with in-
travenous antibiotic. Gastrostomy was performed 3 weeks 
after this incident with no complications.
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Clinical outcome
From the 17 patients, 2 patients were lost for follow-up 
before the first month of gastrostomy. Twelve patients died 
on the course of the advanced disease. Time from PEG tube 
placement to death ranged from 2 months to 1 year (Table 
2). Mean survival time after the procedure of these decease 
patients was 5.9 months. Other 3 patients are alive and follo-
wed by the enteral nutrition team, with 6, 14 and 17 months 
after gastrostomy, a mean time of 12 months, increasing the 
survival after the procedure.
TABLE 2 - Time from gastrostomy to death (12 patients)
Time from gastrostomy to death (month)
<1 0
1-3 4
4-6 5
>6 3
Nutritional evolution
BMI and laboratory data were evaluated at the day of 
gastrostomy (baseline), 1 and 3 months later. Looking to 
our 17 patients, the available data demonstrate that, despite 
of the advance cancers, patients are referred for gastrostomy 
with reasonable mean BMI (21.3 ± 3.5 kg/m2) and laboratory 
parameters, including albumin (3.76 ± 0.62 g/dL), transferrin 
(181.9 ± 45.5 mg/dL) and total cholesterol (162.9 ± 30.9 mg/
dL). Globally, mean BMI and laboratory parameters were 
roughly stable in the 1 month and 3 months evaluation, but 
some patients died or were lost for follow-up (Table 3). Look-
ing to the 10 patients, with available data at baseline, 1 and 3 
months (Table 4), mean BMI and laboratory parameters were 
also roughly stable in the 1 month and 3 months evaluation.
DISCUSSION
Patients with advanced esophageal cancer have signifi-
cant dysphagia, weight loss and malnutrition, that is often 
worsened during chemotherapy and radiotherapy, by muco-
sitis and esophagitis(2, 9). They need an effective nutritional 
support.
There are many studies where enteral nutrition by PEG 
compared with nasogastric tube achieves many nutritional 
advantages. In addition, PEG feeding has a simple manage-
ment which do not requires long feeding times for each meal, 
as needed with a thin diameter of the nasogastric tube. Even 
more important in this clinical setting of palliation, PEG as 
a minor interference with the patient’s life, regarding comfort 
and esthetic aspects(12, 13, 16).
As expected all 17 proximal esophageal carcinomas were 
squamous cell carcinoma(6). All patients were male. This gen-
der specificity is probably related with tobacco and alcohol 
consumption of male patients(6, 11, 15).
Gastrostomy should performed be as early as possible. 
Early insertion may be easier because the stenosis of  the 
esophagus is less pronounced than during the later stages(5). 
Enteral feeding support must start before the decline of the 
nutritional status. In our study most of gastrostomies were 
performed in the first 2 months after the diagnosis.
There were no technical failures and endoscopic gastros-
tomy was performed in all of the patients proposed for the 
procedure. There were few complications related with the 
procedure and only one was a major complication, a BBS, 
an uncommon complication of PEG tube placement, that 
occurs when the internal bumper of a PEG tube lodges any-
where between the gastric wall and the skin. In most cases 
occurs months after the procedure, but is known that patients 
like our case, with malignant diseases, poor nutritional con-
dition and rapid weight gain after PEG placement, have a 
greater risk of BBS(10). Probably, the regular follow-up and the 
care taken in education of patients and caregivers prevented 
the occurrence of more complications in our patients. It has 
been described, that patients with head and neck cancer un-
dergoing PEG by the pull technique may develop abdominal 
wall metastases, by cancer seeding(12, 13). This occurs rarely, 
and there were no cases on our study.
TABLE 4. Evolution of BMI and laboratory markers in patients with data available at the 3 months follow-up
Baseline (n = 10) 1 month (n = 10) 3 months (n = 10)
BMI (kg/m2) 22.6 (± 3.2) 22.1 (± 2.8) 20.6 (±3,0)
Albumin (g/dL) 3.95 (± 0.52) 3.69 (± 0.8) 3.9 (± 0.47)
Transferrin (mg/dL) 203.1 (± 37.3) 205.8 (± 45.8) 216.4 (± 34.1)
Cholesterol (mg/dL) 174.3 (± 31.2) 181.1 (± 47.1) 196.2 (± 31.9)
TABLE 3. Evolution of BMI and laboratory markers in all patients included 
Baseline (n = 17) 1 month (n = 15) 3 months (n = 10)
BMI (kg/m2) 21.3 (± 3.5) 21.0 (± 3.1) 20.6 (± 3.0)
Albumin (g/dL) 3.76 (± 0.,62) 3.7 (± 0.7) 3.9 (± 0.47)
Transferrin (g/dL) 181.9 (± 45.5) 194.4 (± 43.6) 216.4 (± 34.1)
Cholesterol (g/dL) 162.3 (± 30.9) 166.4 (± 47.1) 196.2 (± 31.9) 
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Clinical and nutritional evaluation was performed at the 
time of gastrostomy, and 1 and 3 months later. As expectable 
in advanced disease, four patients died before the 3 months 
follow-up. Two more patients were lost for follow-up. There-
fore data from 3 months follow-up refers to a smaller number 
of patients. Nevertheless, when we compare evolution of the 
10 patients with data available at the 3 months follow-up, 
values are roughly similar.
With our data is evident the stable BMI and serum 
albumin, and an improvement in transferrin and choles-
terol values. The selected laboratory values are known as 
biomarkers of prognosis and nutritional and inflammatory 
status(4, 11). In advanced cancer patients it is not expectable 
that inflammatory status of significantly decreases. To the 
best of our knowledge, the stability or improvement of these 
laboratory markers, in patients with growing cancers, must 
reflect efficient nutritional support, suggesting that even in 
this poor clinical setting some improving could be achieved.
Guidelines do not recommend PEG in palliative patients 
with an unfavorable prognosis or an incurable disease, be-
cause in most of them the mean survival time was less than 
2 months. Nevertheless, in our experience, decision should 
always be individualized(1, 8, 14). In the patients we evaluate 
with unfavorable prognosis and under palliative treatment, 
Grilo A, Santos CA, Fonseca J. A gastrostomia percutânea endoscópica na paliação nutricional do câncer do esôfago proximal sem possibilidade de 
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RESUMO – Contexto - O câncer do esôfago é frequentemente diagnosticado num estádio avançado, com mau prognóstico. A maioria dos pacientes com 
câncer avançado do esôfago sofre de disfagia que contribui para a desnutrição e perda de peso. A colocação de endopróteses é uma forma de paliação 
muito difundida. Contudo, as próteses muito próximas do esfíncter esofágico superior são mal toleradas pelos doentes, não sendo uma opção adequada 
se o câncer for muito proximal. Habitualmente, as recomendações para gastrostomia percutânea não incluem a paliação nutricional nestes doentes, 
mas a gastrostomia percutânea endoscópica pode ser a melhor forma de suporte nutricional no câncer avançado. Objetivo - Avaliação retrospectiva 
dos doentes com disfagia por câncer avançado do esôfago em que a gastrostomia percutânea endoscópica foi a forma de paliação nutricional, sem 
expectativa de retomar a ingestão oral. Método - Selecionaram-se doentes adultos com câncer irressecável do esôfago, com confirmação histológica 
e com localização proximal, impedindo a colocação de prótese, com a radioterapia e quimioterapia paliativas, usando a gastrostomia percutânea 
endoscópica para a nutrição entérica. Avaliaram-se dados clínicos e laboratoriais, incluindo o sucesso da gastrostomia, complicações e sobrevida após 
a gastrostomia e evolução do índice de massa corporal, albumina, transferrina e colesterol. Resultados - Foram incluídos 17 homens com carcinoma 
epidermoide no estádio III ou IV, com média de idade de 60,9 anos. A maioria consumia tabaco e bebidas alcoólicas. Todos foram submetidos a 
radioterapia ou quimioterapia. A gastrostomia endoscópica foi bem-sucedida em todos, embora nove tenham necessitado de dilatação prévia. A 
maioria foi gastrostomizada nos 2 meses subsequentes ao diagnóstico. Ocorreu uma “buried bumper syndrome”, resolvida com substituição do tubo e 
quatro complicações menores. Não houve implantação de metástases, nem mortalidade associada ao procedimento. Dois doentes foram perdidos e 12 
morreram. Três doentes estão vivos 6, 14 e 17 meses após a gastrostomia e ainda estão aumentando a sobrevida média. Os valores médios do índice de 
massa corporal e da avaliação laboratorial mantiveram-se estáveis 1 e 3 meses após a gastrostomia. Conclusão - Em pacientes com câncer avançado do 
esôfago, em que só a terapêutica paliativa é possível, o suporte nutricional é facilmente obtido com gastrostomia percutânea endoscópica, permitindo 
aos pacientes permanecer em suas casas por um longo período. A nutrição por gastrostomia percutânea endoscópica deveria ser considerada, por 
rotina, como a opção definitiva para paliação nutricional em pacientes com câncer do esôfago proximal em que a colocação de prótese não é possível.
DESCRITORES – Gastrostomia. Neoplasias esofágicas. Apoio nutricional. 
insertion of a PEG tube was discussed with the patient and 
caregivers. The mean survival time after the procedure, in 
our deceased patients, was 5.9 months, and there are still 
patients alive, increasing this survival period. This is a period 
of time clearly in agreement with the general guidelines for 
PEG(8, 14). During this time we achieved nutritional support 
to our patients, and contributed for a comfort and a better 
nutritional support in the last months of life. Patients could 
be cared at their homes with their families, even keeping 
some social activities. Our experience demonstrates that an 
important number of esophageal cancer patients, unsuitable 
to curative therapy, have a significant survival expectance and 
PEG feeding should be more often proposed to these patients.
CONCLUSION
Patients with advanced upper esophageal cancer where 
only palliative treatment is possible need a good nutritional 
support. In our experience, this is easily achieved with PEG, 
and allowing dysphagic patients to be stable at their homes, 
without need for hospitalization, and surviving a significant 
period of time. PEG feeding should be considered as defini-
tive nutritional palliation in patients with upper esophageal 
cancer unsuitable for esophageal stenting.
Grilo A, Santos CA, Fonseca J.  Percutaneous endoscopic gastrostomy for nutritional palliation of upper esophageal cancer unsuitable for esophageal stenting
v. 49 – no.3 – jul./set. 2012 Arq Gastroenterol 231
REFERENCES
1. Angus F, Burakoff R. The percutaneous endoscopic gastrostomy tube: medical 
and ethical issues in placement. Am J Gastroenterol. 2003;98:272-7.
2. Besharat S, Jabbari A, Semnani S, Keshtkar A, Marjani J. Inoperable esophageal 
cancer and outcome of palliative care. World J Gastroenterol. 2008;14:3725-8.
3. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241-52.
4. Guerra L, Rosa A, Romani R, Gurski R, Schimer C, Kruel CD. Serum transferrin 
and serum prealbumin as markers of response to nutritional support in patients 
with esophageal cancer. Nutr Hosp. 2009;24:241-2.
5. Hunter J, Lauretano L, Shellito P. Percutaneous endoscopic gastrostomy in head 
and neck cancer patients. Ann Surg. 1989;210:42-6.
6. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. 
CA Cancer J Clin. 2011;61:69–90.
7. Khoshbaten M, Naderpour M, Mohammadi G, Alipoor SH, Estakhri R, Fazeli 
Z. Epidemiology of esophageal lesions in patients with head and neck squamous 
cell carcinoma. Asian Pac J Cancer Prev. 2010;11:863-5.
8. Löser C, Aschl G, Hébuterne X, Mathues-Vliegen EM, Muscaritoli M, Niv Y, 
Rollins H, Singer P, Skelly RH. ESPEN guidelines on artificial enteral nutrition 
— percutaneous endoscopic gastrostomy (PEG). Clin Nutr. 2005;24:848–61.
9. Marin FA, Lamônica-Garcia VC, Henry MA, Burini RC. Grade of esophageal 
cancer and nutritional status impact on postsurgery outcomes. Arq Gastroenterol. 
2010;47:348-53.
10. Meine G, Lukashok H, Mello G, Mansur G, Guimarães D, Carvalho R. Buried 
bumper syndrome as a complication of percutaneous endoscopic gastrostomy in 
cancer patients: the Brazilian experience. Dig Endosc. 2007;19:22-5.
11. Raynaud-Simon A, Revel-Delhom C, Hébuterne X; French Nutrition and Health 
Program; French Health High Authority. Clinical practice guidelines from the 
French health high authority: nutritional support strategy in protein-energy 
malnutrition in the elderly. Clin Nutr. 2011;30:312-9.
12. Sironi A, Arcovio C, Bergamini C, Colatruglio S, Gavazzi C. Indications for per-
cutaneous fluoroscopic gastrostomy in palliative head and neck cancer patients. 
Nutr Ther Metab. 2010;28:143-7.
13. Stockeld D, Fagerberg J, Granström L, Backman L. Percutaneous endoscopic 
gastrostomy for nutrition in patients with oesophageal cancer. Eur J Surg 
2001;167:839-44.
14. Stroud M, Duncan H, Nightingale J; British Society of Gastroenterology: guidelines 
for enteral feeding in adult hospital patients. Gut. 2003;52(Suppl VII):VII1-VII12
15. Thuler FP, Forones NM, Ferrari AP. Neoplasia avançada de esófago – diagnóstico 
ainda muito tardio. Arq Gastroenterol. 2006;43:206-11.
16. Zuercher B, Grosjean P, Monnier P. Percutaneous endoscopic gastrostomy in head 
and neck cancer patients: indications, techniques, complications and results. Eur 
Arch Otorhinolaryngol. 2011;268:623-9.
Received 31/1/2012.
Accepted 28/2/2012.
